Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: Sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis

Modern Rheumatology

Volumn 24, Issue 2, 2014, Pages 304-309

  Yumura, Wako ^a   Kobayashi, Shigeto ^b   Suka, Machi ^c   Hayashi, Taichi ^d   Ito, Satoshi ^e   Nagafuchi, Hiroko ^f   Yamada, Hidehiro ^f   Ozaki, Shoichi ^f  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e Niigata Rheumatic Centre   (Japan)

^f ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BVAS (Birmingham vasculitis activity score); Interstitial pneumonia; Microscopic polyangiitis; MPO ANCA associated vasculitis; Rapidly progressive glomerulonephritis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PREDNISOLONE;

AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE SEQUENCE; DRUG MEGADOSE; FEMALE; HUMAN; JAPANESE (PEOPLE); LUNG; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MYELOPEROXIDASE ANCA ASSOCIATED VASCULITIS; NERVOUS SYSTEM; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; THORAX; VALIDITY;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 84898837906     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.854075     Document Type: Article

References (28)

1. Jennette JC , Falk RJ. Clinical and pathological classification of ANCA-Associated vasculitis: what are the controversies? Clin Exp Immunol. 1995 ; 101 : 18-22.
2. Falk R J, Jennette J C.A nti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. NEngl J Med. 1988 ; 318 : 1651-7.
3. van der Woude F J, Rasmussen N , Lobatto S , W iik A , Permin H , van Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985 ; 1 : 425-9.
4. Fujimoto S , Uezono S , Hisanaga S , Fukudome K , Kobayashi S , Suzuki K, et al. Incidence of ANCA-Associated primary renal vasculitis in Miyazaki prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006 ; 1 : 1016-22.
5. Luqmani R A, Bacon P A, Moots R J, Janssen B A, Pall A , Emery P , et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994 ; 87 : 671-8.
6. Ozaki S, Nakabayashi K, Tomino Y, Koyama T.A prospective, open-labeled, and multi-center trial of standard protocols for MPOANCA-Associated vasculitis by Japanese Study Group for MPOANCA-Associated vasculitis (JMAAV). Annual report 2005 of the Research Group for Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan. 2006. p. 199-323.
7. Ozaki S.ANCA-Associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007 ; 56 : 87-96.
8. Flossmann O , Bacon P , de Groot K , Jayne D , Rasmussen N , Seo P , et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007 ; 66 : 283-9 2.
9. Ozaki S , Atsumi T , Hayashi T , Ishizu A , Kobayashi S , Kumagai S , et al. Severity-based treatment for Japanese patients with MPOANCA-Associated vasculitis: the JMAAV study. Mod Rheumatol. 2011 ; 22 : 394-404.
10. Luqmani RA , Exley AR , Kitas GD , Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol. 1997 ; 11 : 423-46.
11. Luqmani R.Evaluation of vasculitis disease activity in Europe. Eur J Intern Med. 2001 ; 12 : 401-2.
12. Jayne D R, Rasmussen N.Treatment of antineutrophil cytoplasm autoantibody-Associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc. 1997 ; 72 : 737-47.
13. de Groot K , Rasmussen N , Bacon PA , Tervaert JW , Feighery C , Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum. 2005 ; 52 : 2461-9.
14. Benenson E , Fries J W, Heilig B , Pollok M , Rubbert A.High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol. 2005 ; 24 : 251-7.
15. Danieli M G, Cappelli M , Malcangi G , Logullo F , Salvi A , Danieli G.Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004 ; 63 : 1649-54.
16. Jayne D R, Rasmussen N , Andrassy K , Bacon P , Tervaert J W, Dadoniene J , et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. NEngl J Med. 2003 ; 349 : 36-44.
17. Jayne DR , Chapel H , Adu D , Misbah S , O'Donoghue D , Scott D , et al. Intravenous immunoglobulin for ANCA-Associated systemic vasculitis with persistent disease activity. QJM. 2000 ; 93 : 433-9.
18. Booth A , Harper L , Hammad T , Bacon P , Griffith M , Levy J, et al. Prospective study of TNFalpha blockade with infliximab in antineutrophil cytoplasmic antibody-Associated systemic vasculitis. JAm Soc Nephrol. 2004 ; 15 : 717-21.
19. Metzler C , Fink C , Lamprecht P , Gross W L, Reinhold-Keller E.Maintenance of remission with lefl unomide in Wegener's granulomatosis. Rheumatology (Oxford). 2004 ; 43 : 315-20.
20. Bartolucci P , Ramanoelina J , Cohen P , Mahr A , Godmer P , Le Hello C.et al. Efficacy of the anti-TNF-Alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002 ; 41 : 1126-32.
21. Birck R , W arnatz K , Lorenz H M, Choi M , Haubitz M , Grunke M , et al. 15-Deoxyspergualin in patients with refractory ANCA-Associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. JAm Soc Nephrol. 2003 ; 14 : 440-7.
22. Joy MS , Hogan SL , Jennette JC , Falk RJ , Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transpl. 2005 ; 20 : 2725-32.
23. Gayraud M , Guillevin L , Le Toumelin P , Cohen P , Lhote F , Casassus P , et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001 ; 44 : 666-75.
24. Cruz B A, Ramanoelina J , Mahr A , Cohen P , Mouthon L , Cohen Y , et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology (Oxford). 2003 ; 42 : 1183-8.
25. Lane S E, W atts R A, Shepstone L , Scott D G.Primary systemic vasculitis: clinical features and mortality. QJM. 2005 ; 98 : 97-111.
26. Koldingsnes W , Nossent H.Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford). 2002 ; 41 : 572-81.
27. Itabashi M , Takei T , Yabuki Y , Suzuki H , Ando M , Akamatsu M , et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-Associated vasculitis in Japan. Nephron Clin Pract. 2010 ; 115 : c21-7.
28. Suzuki Y , Takeda Y , Sato D , Kanaguchi Y , Tanaka Y , Kobayashi S , et al. Clinicoepidemiological manifestations of RPGN and ANCAassociated vasculitides: an 11-year retrospective hospital-based study in Japan. Mod Rheumatol. 2010 ; 20 : 54-62.